Pile, Kevin (2005) Methotrexate. In: Day, Richard O., Furst, Daniel E., van Riel, Piet L.C.M., and Bresnihan, Barry, (eds.) Antirheumatic Therapy: actions and outcomes. Progress in Inflammation Research . Birkhauser , Switzerland, pp. 175-197.

PDF (Published version) Restricted to Repository staff only

Abstract

This publication does not have an abstract. The Introduction is displayed as the abstract.

Methotrexate (MTX) is a folate analogue originally developed in the 1940s as a highly selective inhibitor of dihydrofolate reductase (DHFR). Its use in the reduction of rheumatoid arthritis (RA) synovitis was first reported in a 1951 paper on six RA patients by Gubner and Ginsburg and explained as a cytotoxic effect on proliferating lymphocytes. Subsequently its efficacy in RA was proven in a series of papers in the mid 1980s and it is now the mainstay of RA therapy, both alone and in combination, as recommended in the guidelines of the American College of Rheumatology 2002 [1].

Item ID:	7308
Item Type:	Book Chapter (Research - B1)
ISBN:	3-7643-6595-1
Keywords:	anti-rheumatic medications; methotrexate; pharmacology; rheumatoid arthritis
Related URLs:	Publisher
Date Deposited:	27 Jan 2010 01:30
FoR Codes:	11 MEDICAL AND HEALTH SCIENCES > 1199 Other Medical and Health Sciences > 119999 Medical and Health Sciences not elsewhere classified @ 60% 11 MEDICAL AND HEALTH SCIENCES > 1101 Medical Biochemistry and Metabolomics > 110199 Medical Biochemistry and Metabolomics not elsewhere classified @ 10% 11 MEDICAL AND HEALTH SCIENCES > 1103 Clinical Sciences > 110322 Rheumatology and Arthritis @ 30%
SEO Codes:	92 HEALTH > 9201 Clinical Health (Organs, Diseases and Abnormal Conditions) > 920116 Skeletal System and Disorders (incl. Arthritis) @ 100%
Downloads:	Total: 4
	More Statistics